Status:
RECRUITING
Enhancement of Quality of Work And Life
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The Dutch Brain Foundation
Conditions:
Parkinson Disease
Hereditary Spastic Paraparesis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Work participation is essential for quality of life, providing purpose, social interaction, financial security, and shaping social status. Work participation is increasingly compromised in people with...
Detailed Description
Work participation is essential for quality of life, providing purpose, social interaction, financial security, and shaping social status and personal identity. Work participation is increasingly comp...
Eligibility Criteria
Inclusion
- having a diagnosis Parkinson Disease, cerebellar ataxia, hereditairy spastic paraparesis, or a slowly progressive neuromuscular or mitochondrial disorder, confirmed by the treating physician (e.g. neurologist, rehabilitation physician)
- aged 18-65 years;
- being employed for at least 8 hours per week (at baseline). This also includes individuals who have reduced their working hours until reaching this threshold of 8 hours per week. Working time may be distributed across multiple working days;
- having the intention to continue to work during the study period of 18 months, to prevent inclusion of participants who plan to retire within the 18-month RCT period;
- being open to talk to the employer or manager about any changes or limitations in work performance (disclosing the diagnosis is not required, by law).
Exclusion
- individuals who are at the beginning of a sick leave procedure (under the Gatekeeper Improvement Act; Wvp);
- being fully self-employed. Partial self-employment in addition to paid employment is allowed, on the condition that the paid employment accounts for more than half of the total weekly working hours;
- having a second employer for over eight hours per week;
- proficiency in the Dutch language is not sufficient;
- severe comorbidity or health-related event that will hamper compliance to the protocol, e.g. in case of a severe cognitive impairment, a relatively abrupt transition to a very progressive manifestation of the disease, a planned surgery.
Key Trial Info
Start Date :
October 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 4 2027
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT06573866
Start Date
October 8 2024
End Date
January 4 2027
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboudumc
Nijmegen, Gelderland, Netherlands, 6525 GA